Introduction to Personalised Medicine

Learn the basics about potential and principles in genetically based treatments

Date icon

Access anytime

Attendance icon


Language icon


Price icon
2,000 DKK ex VAT

(app. 269 EUR ex VAT)


Personalised Medicine supports patients in receiving an optimal and effective treatment with a minimum of risk of adverse events.

As this type of treatment is still relatively new, many have the need for an introduction to the basics of personalised medicine: what is the potential? What types of analyses are needed? What is the flow in collaboration and responsibilities among stakeholders, e.g. doctors, analysts and patients?

By completing the 7 modules included in this self-access online course, you acquire basic knowledge about personalised medicine: The potential of genetic analysis of drug metabolising enzymes, transporters and receptors, and how to use this information in clinical practice.

You can access the 7 online modules whenever is most convenient for you. Please note that your access expires one year from the time you sign up.

After finishing each module, you must answer a number of questions related to that specific module before you can access the next module.

We recommend you to contact Genetelligence via Atrium if you have questions that needs clarification. 


  • Personalised medicine
  • Optimised medical treatment
  • Reduction of adverse events
  • Pharmacogenomics
  • Pharmacokinetics
  • Pharmacodynamics


Do you need help choosing the right course? 

We are ready to help you at +45 39 27 60 60 or 

Stay tuned with Atrium's newsletter 

Save information for later
Read more

Course leader & lecturers

  • Lone Fisker
    Course leader
    Executive MBA, CEO
    GeneTelligence ApS

Watch the video

Is this course for you?

The course is for you, if you wish to understand the potential and principles of personalised medicine and work within the healthcare sector as a general practitioner, specialist, nurse, pharmacist or researcher, and you are interested in personalised medical treatment.

What you will learn

  1. Basic knowledge about personalised medicine and how to use it in clinical practice 
  2. Various perspectives on the potential and priciples of personalised medicine 
  3. Knowledge about legals aspects in relation to ethics and GDPR
  4. Understading of the areas of responsibility among stakeholders e.g. doctors, analysts and patients  

What your company will get

  1. An employee with an understanding of personalised medicine and how ti use it in clinical practice 
  2. An employee with an understanding of various perspectives on personalised medicine 
  3. An employee with insights about legal aspects and areas of responsibility in relations to personalised medicine 

Course agenda

Session 0
Module 1:

How pharmacogenomic testing can support the healthcare system in providing the right medical treatment, to the right patient, in the right dose, at the right time..

Session 1
Module 2:

Legal aspects in relation to ethics and GDPR.

Session 2
Module 3:

How pharmacogenomic data can be translated and applied in the clinic. And the internationally peer-reviewed pharmacogenetic databases, treatment guidelines and regulatory framework that will guide your way.

Session 3
Module 4:

Factors beyond pharmacokinetics and pharmacodynamics, e.g. how genetic variation can help shed light on different responses to drugs between patients.

Session 4
Module 5:

The analytical aspects in the laboratory: what is the laboratory process flow? How is the genotype translated into the phenotype? What are the limitations and advantages of several platforms?

Session 5
Module 6:

Pharmacogenomics is not something in the future – it is here today. Patients can already benefit from personalised medicine, e.g. capecitabine/DPYD, clopidogrel/CYP2C19, antidepressants/CYP2D6, pain/CYP2D6 and more.

Session 6
Module 7:

Pharmacogenomics is only one factor that affects the dose-response relationship of drugs. Co-medication, kidney function, lifestyle etc. are well-known contributors affecting the dose-response relationship of drugs.

Practical information
Sometimes things change. This is the expected programme.

Course leader

Lone Fisker
Executive MBA, CEO
GeneTelligence ApS

You may also be interested in these courses

Want to know more or need help?

Contact Client Manager Christina Spangsberg at +45 39 15 09 22

Send me a message